Catalyze Group’s Post

Wow, I'm delighted to see this published and shared. This #EIC #Transition €2.5M was (and still is) an important milestone for Vector Bioscience Cambridge and our #DrugDelivery platform. It is enabling our #nanoshuttle technology to generate robust in vivo data, validate scalable manufacturing, and build the regulatory and CMC foundations required for commercialisation. Each of these steps moves us closer to translating our science into real therapeutic options and making a tangible impact for patients. A huge #thank you to the entire team for the professionalism, structure and ease you brought to the process. EIC is demanding, and your clarity and input made a real difference. Wishing you continued success ahead! Onward to the next win! 🙌🏽 #EIC #Transition #GrantSucess #Innovation #TeamWork #Collaboration

A promising breakthrough to enhance the effectiveness of CAR-T therapies What if we could significantly reduce relapse rates after CAR-T treatment? Scientists have developed a new manufacturing method based on a multi-cytokine matrix, enabling the production of immune cells that are: 👉 longer-lasting 👉 capable of self-renewal 👉 potentially more effective at targeting tumor cells 🧬 This approach could mark a major step forward in cell therapy for oncology by improving CAR-T cell persistence — a key factor in preventing relapse. 👉 An innovation that paves the way for more durable and resilient cancer treatments. 🙂 Another encouraging news from Groupe UIG 🚀 Read: https://lnkd.in/eiXx4g6i #CARTtherapy #OncologyInnovation #Immunotherapy #BiotechInnovation #CellTherapy #CancerResearch #NextGenMedicine #PrecisionOncology #TranslationalResearch #LifeSciences #MedTech Myst Therapeutics (acquired by Turnstone Biologics) Triumvira Immunologics, Inc. BC Cancer Genome Canada Fate Therapeutics Inc. Adaptimmune Zymeworks Inc.

A promising breakthrough to enhance the effectiveness of CAR-T therapies What if we could significantly reduce relapse rates after CAR-T treatment? Scientists have developed a new manufacturing method based on a multi-cytokine matrix, enabling the production of immune cells that are: 👉 longer-lasting 👉 capable of self-renewal 👉 potentially more effective at targeting tumor cells 🧬 This approach could mark a major step forward in cell therapy for oncology by improving CAR-T cell persistence — a key factor in preventing relapse. 👉 An innovation that paves the way for more durable and resilient cancer treatments. 🙂 Another encouraging news from Groupe UIG 🚀 Read: https://lnkd.in/e8FXSSQZ #CARTtherapy #OncologyInnovation #Immunotherapy #BiotechInnovation #CellTherapy #CancerResearch #NextGenMedicine #PrecisionOncology #TranslationalResearch #LifeSciences #MedTech Myst Therapeutics (acquired by Turnstone Biologics) Triumvira Immunologics, Inc. BC Cancer Genome Canada Fate Therapeutics Inc. Adaptimmune Zymeworks Inc.

Sprint Bioscience presents new preclinical data from the company’s DCPS research program will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place on April 17, 2026, in San Diego, USA. 🟣https://lnkd.in/dST7FfzA The poster presentation summarizes new research findings supporting DCPS inhibition as a valid therapeutic strategy for patients with acute myeloid leukemia (AML). The results deepen the scientific understanding of DCPS biology and highlights its potential to improve patient stratification in AML. The poster “Integrated FHIT and IDH2 biomarkers predict synthetic lethal response to DCPS inhibition in acute myeloid leukemia” will be presented by Madhurendra Singh, Associate Principal Scientist at Sprint Bioscience. The AACR Annual Meeting is one of the world’s most prominent scientific conferences in cancer research, bringing together leading researchers, clinicians, and drug developers. More information about the conference is available on AACR’s official website: https://lnkd.in/gV787au8   #AACR #oncology #immunooncology #DCPS #biomarker ▪️ Subscribe for future press releases  https://lnkd.in/df2Fhn-5

Looking forward to presenting our latest work at the American Association for Cancer Research Annual Meeting (AACR). We have been exploring how targeting RNA metabolism can benefit patients with Acute Myeloid Leukemia, with a focus on identifying biomarkers for DCPS inhibition. Proud of the work done at Sprint and excited to share and discuss with the community.

Huge news from VUB spin-off etherna: their collaboration with Almirall has resulted in the official nomination of LAD116 as a preclinical candidate for non-melanoma skin cancer. 🧬 Using etherna's cutting-edge mRNA and lipid nanoparticle (LNP) platform, this therapy is now heading toward GMP manufacturing and intended Phase I trials. Since its founding at Vrije Universiteit Brussel in 2013, etherna has been a leader in translating academic excellence into differentiated RNA therapeutics. 👉 Read the full article: https://lnkd.in/eXac5zSx 🔎 More on etherna: https://lnkd.in/eSqCAyGv We are excited to see what this next chapter brings for oncology patients worldwide. Bernard Sagaert Kris Thielemans #mRNA #Biotech #Innovation #SkinCancer #LNP #SpinOff

🧬 Greenwich LifeSciences, Inc. (Nasdaq: GLSI) Accelerates Phase 3 Breast Cancer Trial Enrollment Greenwich LifeSciences, Inc. reports its Phase 3 breast cancer recurrence prevention trial is now screening at a rate of 800+ patients per year — a 33% increase from the prior 600/year pace. Screening has climbed to ~200 patients per quarter across U.S. and EU sites, driven by newly activated sites and stronger momentum at existing centers. 💡 Why this matters: • 1,000+ patients screened to date • 250-patient treatment arm fully enrolled • Preliminary open-label data in that arm shows ~80% reduction in recurrence rate (preliminary, ongoing study) A faster screening rate supports quicker enrollment, more rapid data accumulation, and improved visibility toward key trial milestones. Operational momentum is building — and the early recurrence signal remains a central part of the long-term thesis. 🔗 Full release: https://lnkd.in/erbgJtyG Fierce Biotech Genetic Engineering & Biotechnology News PharmaVoice #GLSI #Biotech #ClinicalTrials #BreastCancer #Oncology #SmallCapStocks #Investing

🧬 GPCR drug targets: Montreal biotech Kainova reports positive Phase I cancer results During my PhD in neuroscience, I spent years studying μ-opioid receptors — part of the G protein–coupled receptor (GPCR) family, which still represents one of the largest classes of drug targets. A Montreal biotech, Kainova Therapeutics — specialized in GPCR-targeted therapies — just reported positive Phase I results for its immuno-oncology program. 📊 Early results showed: – Favorable safety profile – Early signs of anti-tumor activity – Potential to overcome tumor immune suppression – First clinical validation of Kainova’s GPCR-focused platform 🧠 The therapy DT-9081 targets the EP4 receptor, a GPCR involved in prostaglandin-mediated immune suppression within the tumor microenvironment. By blocking EP4 signaling, the approach aims to help restore anti-tumor immune responses. 💡 Another encouraging signal that Montreal’s biotech ecosystem continues to advance innovative cancer therapies.

One of oncology's longest-standing delivery challenges — endosomal entrapment — may finally have a solution. iDEL Therapeutics GmbH, a freshly launched biotech out of Dortmund, Germany, is pioneering a cytosolic drug delivery platform that bypasses the endosome entirely. By hijacking tumor-specific transporter proteins, their synthetic shuttle deposits payloads — including full-sized antibodies and nanobodies — directly into the cytosol of cancer cells. The technology originated not in oncology, but in imaging research. A serendipitous observation about how a contrast agent scaffold was being selectively absorbed by tumor cells set the company on a path toward a platform that could unlock historically undruggable intracellular targets. With €9M in seed funding and in vivo proof-of-concept data in hand, iDEL is now advancing two lead programs: one targeting a high-priority undisclosed oncogene, and a Multi-Cancer Drug Conjugate (MDC) designed to work across 50+ cancer cell types — no tumor-specific antigen required. We spoke with Co-Founder and CEO Marcus Kostka, PhD about the science, the pipeline, and what this could mean for the future of cancer treatment. 🔗 Read the full story: https://lnkd.in/eC3M3Vz4 #Oncology #DrugDelivery #Biotech #CancerResearch #DrugDiscovery

My latest for R&D World is out — and it's a fascinating one for anyone working in drug delivery or oncology. Endosomal entrapment has long been one of the key barriers to intracellular drug delivery, particularly for large molecules like antibodies and nanobodies. Once internalized via receptor-mediated endocytosis, many therapeutics never escape the endosome — they're degraded before ever reaching their target. iDEL Therapeutics GmbH is taking a fundamentally different approach. Rather than engineering around the endosome, their synthetic shuttle technology bypasses it altogether — binding to transporter proteins overexpressed on tumor cells that naturally route their cargo directly into the cytosol. What struck me most talking with Co-Founder and CEO Marcus Kostka, PhD: the platform's origin wasn't in oncology at all. It grew out of contrast agent imaging research, where co-founder Andreas Briel noticed a scaffold being selectively absorbed by tumor cells — without initially understanding why. That serendipitous observation eventually led to the identification of the specific transporters involved, and a new therapeutic modality was born. The company has already demonstrated in vivo delivery of a functional nanobody into the tumor cytosol via IV administration — and is now advancing two lead programs with €9M in seed funding: one against an undisclosed high-priority intracellular oncotarget, and a Multi-Cancer Drug Conjugate (MDC) platform that works across 50+ cancer cell types without requiring a tumor-specific antigen. Full story at the link below. 🔗 https://lnkd.in/eM5-RukV #DrugDelivery #Oncology #Biotech #IntracellularDelivery #CancerResearch #DrugDiscovery #Nanobody